Adjust Font Increase Font Decrease Font

The Catalyst

Incremental Innovation in the Development of Biopharmaceuticals Part 2

Eric A. Utt, Ph.D., Director, Worldwide Policy for Pfizer, wraps up the second of a two-part series on incremental innovation. During the 1940s and 1950s, tuberculosis patients were housed in sanitariums, frequently alongside patients who had been institutionalized with various mental illnesses. At this time, mental disorders such as schizophrenia and depression were not accessible [...]

What We Learn From Clinical Trials

A recent op-ed in Forbes offers a welcome rebuttal to misguided criticism of the conduct of clinical trials by the biopharmaceutical industry by refuting the notion that “medicine is broken” partly due to the hiding of “negative” clinical trial results.  First, it explains how even clinical trials that do not validate the premise that they [...]

Incremental Innovation Series: Focus on Rheumatoid Arthritis

As part of our ongoing incremental innovation series on the Catalyst, Thomas F. Goss, PharmD, Senior Vice President, Boston Healthcare Associates, highlights the importance of medical progress for patients suffering from rheumatoid arthritis in his very own blog post:  The weather is warming (finally) here in the northeast, and like many families, we found ourselves [...]

The Spotlight

Similar to other statements below, I greatly appreciate the contribution of the PhRMA Foundation towards my career with a Pre Doctoral Fellowship in Pharmacology/Toxicology. The PhRMA Foundation's generosity has been essential to the development of leaders who are passionate about their research. This fellowship will enable me to focus on my project investigating the pharmaco- and toxicogenomics of anticancer agents. Ultimately, I will strive to improve patient care through translational endeavors. Thank you so much for supporting us!

February 1 at 9:48pm